Some prostate cancers ‘can be diagnosed without biopsy’ – study
Some prostate cancers can be diagnosed without the need for an invasive biopsy, according to a new study.…
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
Delix Therapeutics was the first well-funded ‘non-hallucinogenic psychedelic’ drug developer to emerge, in many ways defining the category.…
Psychiatric hospital beds save lives
Dear Editor, The closure of beds for patients suffering from severe mental illness is the worst news possible…
What Happens to Your Body When You Take Zinc Supplements?
Medically reviewed by Suzanne Fisher, RD Zinc is a mineral that supports immune function and other bodily processesCredit:…
‘It’s life changing,’: At this Lehigh Valley CrossFit class, the average age is 70 | Allentown Area
EMMAUS, Pa. – Every Tuesday and Thursday at Free Will CrossFit in Emmaus seniors take over the gym.…
Tire-derived chemical pollution in China could keep rising despite vehicle electrification
image: National-scale emissions, multimedia fate, and future projections of tire-derived 6PPD in China view more Credit: Wentao Teng,…
Mayo Clinic hires Honeywell Aerospace alumnus as new CIO – Post Bulletin
ROCHESTER — Mayo Clinic has hired Arun Kumar Bhaskara-Baba as its new chief information officer, filling a position…
Gambling reforms put onus on bookies to flag vulnerable punters
Australian wagering companies will identify their own problem gamblers and cut off betting inducements under a system one…
The 10 Healthiest Breakfasts to Fuel Your Morning
It’s important to start your day with high-grade fuel. This means chowing down on healthy breakfast foods to…
South Africa-born fitness coach dies after collapsing during Hyrox Bangkok
BANGKOK, Aug 18 — South African fitness coach Leroy Saunders died after collapsing and losing consciousness during the…
When Are Psychiatric Comorbidities in IBD Most Likely to Occur?
A cohort study of Swedish patients with inflammatory bowel disease (IBD) found an increased risk of any psychiatric…
EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…